Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Short Interest Down 50.2% in October

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the recipient of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 13,800 shares, a drop of 50.2% from the October 15th total of 27,700 shares. Based on an average daily trading volume, of 158,500 shares, the short-interest ratio is currently 0.1 days.

Biodexa Pharmaceuticals Stock Performance

Shares of BDRX opened at $4.85 on Thursday. Biodexa Pharmaceuticals has a 1 year low of $4.70 and a 1 year high of $220.25.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.